These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34957158)

  • 21. Changes and determination of dosing recommendations for medicinal products recently authorised in the European Union.
    Ehmann F; Papaluca M; Di Giuseppe F; Pani L; Eskova A; Manolis E; Herold R
    Expert Opin Pharmacother; 2015 Apr; 16(6):903-11. PubMed ID: 25773468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncology Products in the European Union: An Analysis of Regulatory Approvals with a CHMP Oral Explanation.
    Oger A; Torqui A; Kester R; Wissink S
    Ther Innov Regul Sci; 2021 Sep; 55(5):1036-1044. PubMed ID: 34041707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation (EC) No 1901/2006 on medicinal products for paediatric use & clinical research in vulnerable populations.
    Lehmann B
    Child Adolesc Psychiatry Ment Health; 2008 Dec; 2(1):37. PubMed ID: 19063722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020.
    Teixeira MM; Borges FC; Ferreira PS; Rocha J; Sepodes B; Torre C
    Front Med (Lausanne); 2022; 9():968272. PubMed ID: 36035431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paediatric Medicines in Europe: The Paediatric Regulation-Is It Time for Reform?
    Toma M; Felisi M; Bonifazi D; Bonifazi F; Giannuzzi V; Reggiardo G; de Wildt S; Ceci A;
    Front Med (Lausanne); 2021; 8():593281. PubMed ID: 33604345
    [No Abstract]   [Full Text] [Related]  

  • 27. Current situation and evolution of the availability of drugs in the paediatric population in Spain.
    Paradas-Palomo JD; Yunquera-Romero L; Gallego-Fernández C
    Farm Hosp; 2024; 48(3):122-128. PubMed ID: 37612184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
    Carr M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Environmental risk assessment of advanced therapies containing genetically modified organisms in the EU.
    Whomsley R; Palmi Reig V; Hidalgo-Simon A
    Br J Clin Pharmacol; 2021 Jun; 87(6):2450-2458. PubMed ID: 33600022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The regulatory system in europe with special emphasis on allergen products.
    Lorenz AR; Luttkopf D; Seitz R; Vieths S
    Int Arch Allergy Immunol; 2008; 147(4):263-75. PubMed ID: 18648190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medicinal plants and their preparations in the European market: Why has the harmonization failed? The cases of St. John's wort, valerian, ginkgo, ginseng, and green tea.
    Bilia AR; Costa MDC
    Phytomedicine; 2021 Jan; 81():153421. PubMed ID: 33291029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory landscape for cell therapy--EU view.
    McBlane JW
    Biologicals; 2015 Sep; 43(5):433-6. PubMed ID: 25997566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
    Enzmann H; Broich K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency.
    Netzer T
    Eur J Cancer; 2006 Mar; 42(4):446-55. PubMed ID: 16129598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chaos to Clarity: Pragmatic Approaches to Overcome Challenges for Successful Implementation of Additional Risk Minimisation Measures in the European Union and the UK by a Marketing Authorisation Holder.
    Hapani K; Parikh N; Pianka K; Patel H
    Pharmaceut Med; 2022 Jun; 36(3):173-188. PubMed ID: 35416591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Old active ingredients in new medicinal products: is the regulatory path coherent with patients' expectations?
    Minghetti P; Musazzi UM; Casiraghi A; Rocco P
    Drug Discov Today; 2020 Aug; 25(8):1337-1347. PubMed ID: 32485225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.